CD3 antibody

CD3 antibodies (or anti-CD3 monoclonal antibodies) are a class of immunomodulatory agents that target the CD3 T-cell co-receptor, which is part of the T-cell receptor (TCR) complex. By binding to CD3, these antibodies can modulate T-cell activation, induce partial T-cell depletion, and promote the induction of regulatory T-cells (Tregs). This mechanism helps restore immune tolerance and control pathogenic autoimmune responses. CD3 antibodies have been widely investigated and approved for clinical use, notably teplizumab (Tzield) for delaying the onset of stage 3 type 1 diabetes, and historically muromonab-CD3 (Orthoclone OKT3) for preventing transplant rejection. Other candidates in this class include otelixizumab, foralumab, and visilizumab, which have been evaluated in autoimmune and inflammatory conditions such as type 1 diabetes, rheumatoid arthritis, and inflammatory bowel disease.

Other names

anti-CD3anti-CD-3anti-CD 3anti-CD3 antibodyanti-CD-3 antibodyanti-CD 3 antibodyanti-CD3 mAbanti-CD-3 mAbanti-CD 3 mAbanti-CD3 monoclonal antibodyanti-CD-3 monoclonal antibodyanti-CD 3 monoclonal antibodyCD3 monoclonal antibodyCD-3 monoclonal antibodyCD 3 monoclonal antibodyCD3-antibodyCD-3-antibodyCD 3-antibody